Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filippo Ceccato

Showing results (121-130 of 159) with videos related to

Pageof 16
Sort By:
Endocrinology|June 14, 2014
Activation of the dopamine receptor type-2 (DRD2) promoter by 9-cis retinoic acid in a cellular model of Cushing's disease mediates the inhibition of cell proliferation and ACTH secretion without a complete corticotroph-to-melanotroph transdifferentiationGianluca Occhi, Daniela Regazzo, Nora Maria Albiger, et al.
The Journal of Clinical Endocrinology and Metabolism|September 3, 2020
RNA Sequencing and Somatic Mutation Status of Adrenocortical Tumors: Novel Pathogenetic InsightsGuido Di Dalmazi, Barbara Altieri, Claus Scholz, et al.
Oncotarget|September 23, 2015
A constitutive active MAPK/ERK pathway due to BRAFV600E positively regulates AHR pathway in PTCGianluca Occhi, Susi Barollo, Daniela Regazzo, et al.
The Journals of Gerontology. Series B, Psychological Sciences and Social Sciences|January 8, 2026
Effect of cognitive training on cortisol levels in patients with neurocognitive disordersMarina De Rui, Giulia Salerno Trapella, Chiara Ceolin, et al.
European Journal of Endocrinology|January 5, 2019
The natural history of autoimmune Addison's disease from the detection of autoantibodies to development of the disease: a long-term follow-up study on 143 patientsLara Naletto, Anna Chiara Frigo, Filippo Ceccato, et al.
Journal of Personalized Medicine|April 30, 2021
What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered QuestionVittoria Basile, Soraya Puglisi, Barbara Altieri, et al.
Journal of Clinical Medicine|November 6, 2019
Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant TreatmentSoraya Puglisi, Anna Calabrese, Vittoria Basile, et al.
European Journal of Endocrinology|February 8, 2024
KDM1A genotyping and expression in 146 sporadic somatotroph pituitary adenomasFanny Chasseloup, Daniela Regazzo, Lucie Tosca, et al.
Endocrine Pathology|April 11, 2025
Multicentric Retrospective Analysis of Oncocytic Adrenocortical Carcinoma: Insights into Clinical and Management StrategiesAntonio Prinzi, Valentina Guarnotta, Guido Di Dalmazi, et al.
Cancers|April 5, 2020
Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical CarcinomaSoraya Puglisi, Anna Calabrese, Vittoria Basile, et al.
Pageof 16

Showing results (121-130 of 159) with videos related to

Sort By:
Pageof 16
Endocrinology|June 14, 2014
Activation of the dopamine receptor type-2 (DRD2) promoter by 9-cis retinoic acid in a cellular model of Cushing's disease mediates the inhibition of cell proliferation and ACTH secretion without a complete corticotroph-to-melanotroph transdifferentiationGianluca Occhi, Daniela Regazzo, Nora Maria Albiger, et al.
The Journal of Clinical Endocrinology and Metabolism|September 3, 2020
RNA Sequencing and Somatic Mutation Status of Adrenocortical Tumors: Novel Pathogenetic InsightsGuido Di Dalmazi, Barbara Altieri, Claus Scholz, et al.
Oncotarget|September 23, 2015
A constitutive active MAPK/ERK pathway due to BRAFV600E positively regulates AHR pathway in PTCGianluca Occhi, Susi Barollo, Daniela Regazzo, et al.
The Journals of Gerontology. Series B, Psychological Sciences and Social Sciences|January 8, 2026
Effect of cognitive training on cortisol levels in patients with neurocognitive disordersMarina De Rui, Giulia Salerno Trapella, Chiara Ceolin, et al.
European Journal of Endocrinology|January 5, 2019
The natural history of autoimmune Addison's disease from the detection of autoantibodies to development of the disease: a long-term follow-up study on 143 patientsLara Naletto, Anna Chiara Frigo, Filippo Ceccato, et al.
Journal of Personalized Medicine|April 30, 2021
What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered QuestionVittoria Basile, Soraya Puglisi, Barbara Altieri, et al.
Journal of Clinical Medicine|November 6, 2019
Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant TreatmentSoraya Puglisi, Anna Calabrese, Vittoria Basile, et al.
European Journal of Endocrinology|February 8, 2024
KDM1A genotyping and expression in 146 sporadic somatotroph pituitary adenomasFanny Chasseloup, Daniela Regazzo, Lucie Tosca, et al.
Endocrine Pathology|April 11, 2025
Multicentric Retrospective Analysis of Oncocytic Adrenocortical Carcinoma: Insights into Clinical and Management StrategiesAntonio Prinzi, Valentina Guarnotta, Guido Di Dalmazi, et al.
Cancers|April 5, 2020
Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical CarcinomaSoraya Puglisi, Anna Calabrese, Vittoria Basile, et al.
Pageof 16